Lates News

According to Every AI Quick News, Shanxi Securities released a research report on September 22, giving a buy rating to Bailing Tianheng (688506.SH). The rating reasons mainly include: 1) Bailing Tianheng is an innovative pharmaceutical company focusing on ADC and multi-antigen therapeutics; 2) iza-bren has shown remarkable preliminary efficacy in phase II clinical trials for EGFR mutation in NSCLC, phase I clinical trials for EGFR wild type, and phase I clinical trials for driver gene mutations other than classic EGFR mutations; 3) T-Bren has shown remarkable preliminary efficacy in phase I clinical trials for HER2+, treated HER2+ HER2ADC, and HER2 low-expressing breast cancer. (Daily Economic News)